- Home
- CDE vs INCY Comparison
CDE vs INCY Comparison
Compare CDE & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | INCY |
|---|---|---|
| Founded | 1928 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 17.0B |
| IPO Year | 1994 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CDE | INCY |
|---|---|---|
| Price | $21.08 | $128.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | $22.40 | ★ $103.52 |
| AVG Volume (30 Days) | ★ 37.3M | 1.8M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 533.33 | ★ 4173.33 |
| EPS | 0.42 | ★ 1.47 |
| Revenue | $709,598,000.00 | ★ $3,394,635,000.00 |
| Revenue This Year | $165.39 | $10.44 |
| Revenue Next Year | $12.10 | $10.99 |
| P/E Ratio | ★ $50.26 | $86.54 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $12.05 | $81.09 |
| 52 Week High | $27.77 | $132.60 |
Technical Indicators
Market Signals| Indicator | CDE | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 66.03 |
| Support Level | $20.58 | $98.50 |
| Resistance Level | $21.47 | $132.60 |
| Average True Range (ATR) | 0.84 | 3.41 |
| MACD | 0.44 | 0.41 |
| Stochastic Oscillator | 87.65 | 88.27 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico generating maximum revenue from United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.